Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol

Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India.
Acta Diabetologica (Impact Factor: 3.68). 09/2008; 46(1):27-33. DOI: 10.1007/s00592-008-0054-7
Source: PubMed

ABSTRACT The purpose of this study was to assess the effects of PPAR-gamma agonists (pioglitazone and rosiglitazone) on mediators of endothelial dysfunction and markers of angiogenesis in patients with type-2 diabetes. Pioglitazone group showed favorable reductions in serum total cholesterol, triglycerides, LDL cholesterol, VLDL cholesterol and increase in HDL cholesterol as compared to rosiglitazone group, after 16 weeks of treatment and also with control group. There was significant reduction of CRP level in pioglitazone and rosiglitazone group. The level of serum TNF-alpha decreased significantly in pioglitazone and mildly decreased in rosiglitazone group. The level of VEGF, IL-8 and Angiogenin were increased in pioglitazone than rosiglitazone group. There were no significant changes observed in the serum angiogenin and IL-8 levels in the control group. Pioglitazone and rosiglitazone therapy in type-2 diabetes subjects have additional benefits of reducing mediators of endothelial dysfunction. Increase in angiogenesis markers in patients receiving pioglitazone could have variable effects in diabetic nephropathy and retinopathy as there may be increased vascular neogenesis. Pioglitazone has advantage over rosiglitazone in lowering lipid and proinflammatory cytokines.

Download full-text


Available from: Manish Mishra, Aug 18, 2015
1 Follower
  • Source
    • "Thus, after weight loss and a decreased inflammatory burden (as evident by a decrease in hs-CRP), a concomitant increase in HDL-C is observed. In support of this potential relation are results obtained from pharmacologic interventions with rosiglitazone that led to a decrease in hs-CRP and an increase in HDL-C [20] [21]. Unfortunately, despite this effect of rosiglitazone, similar to the effects of torcetrapib, another pharmacologic agent that increases HDL-C and decreases CRP [22] , the overall effect of cardiovascular endpoints was dismal [23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine how changes in lipids, liver enzymes, and inflammatory and glycemia markers intercorrelate during prolonged dietary intervention in obese participants with or without type 2 diabetes (T2D). We examined the dynamics and intercorrelations among changes in biomarkers during the 2-y Dietary Intervention Randomized Controlled Trial (DIRECT) in 322 participants (including 46 with T2D; 52 y of age, body mass index 31 kg/m(2)) throughout rapid weight loss (0-6 mo) and weight-maintenance/regain (7-24 mo) phases. The 2-y increase of high-density lipoprotein cholesterol was greater in participants with T2D (+9.41 versus+6.57 mg/dL, P < 0.05), although they tended to have smaller waist circumferences (-2.1 versus -4.0 cm, P = 0.08). In models adjusted for age, sex, and weight loss, the 2-year decrease of triacylglycerols was associated with increases of low-density and high-density lipoprotein cholesterol. An increase of apolipoprotein A1 was associated with a decrease in high-sensitive C-reactive protein (P < 0.05 for all comparisons). Exclusively in participants with T2D, the 2-year decrease in triacylglycerols was further correlated with decreases in apolipoprotein B100 and liver enzymes, and a decrease in fasting glucose correlated with decreases in low-density lipoprotein cholesterol, apolipoprotein B100, and alanine aminotransferase (P < 0.05 for all comparisons). In the entire group, multivariate models adjusted for age, sex, intervention group, and 6-mo weight loss identified decreased high-sensitive C-reactive protein at 6 mo as an exclusive predictor of a greater decrease in triacylglycerols (β = 0.154, P = 0.008) and a greater increase in high-density lipoprotein cholesterol (β = -0.452, P = 0.005) during the subsequent 18 mo. Long-term dietary intervention induces a flow of changes within biomarkers and the cross-talk is likely to be stronger in T2D. A decrease in systemic inflammation during the weight-loss phase may predict greater long-term improvement in lipids (, identifier NCT00160108).
    Nutrition 08/2011; 28(2):131-7. DOI:10.1016/j.nut.2011.04.001 · 3.05 Impact Factor
  • Source
    • "(B.S. Cha). reduction of proinflammatory markers including C-reactive protein (CRP) [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13]. C-reactive protein is an acute-phase reactant that is known as a proinflammatory marker and a predictor of cardiovascular events [14] [15] [16]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Thiazoledinedione is known to have an anti-inflammatory effect besides a hypoglycemic effect. We investigated changes in high-sensitivity C-reactive protein (hsCRP), a proinflammatory marker, after pioglitazone treatment in association with the resulting changes in various metabolic and anthropometric parameters. A total of 93 type 2 diabetes mellitus patients (47 men and 46 women; mean age, 50.0 ± 10.8 years) who were being treated with a stable dose of sulfonylurea or metformin were enrolled in the study. Pioglitazone (15 mg/d) was added to their treatment regimen for 12 weeks, and metabolic and anthropometric measurements were taken before and after pioglitazone treatment. Pioglitazone treatment for 12 weeks decreased serum hsCRP levels (0.83 [1.14] to 0.52 [0.82] mg/L, P < .001) and improved glycemic control (fasting glucose, P < .001; glycosylated hemoglobin, P < .001) and lipid profiles (triglyceride, P = .016; high-density lipoprotein cholesterol, P < .001). Between responders and nonresponders to the hsCRP-lowering effect of pioglitazone, there were significant differences in baseline hsCRP levels and changes in the postprandial glucose and the ratio of visceral fat thickness (VFT) to subcutaneous fat thickness (SFT) (P = .004, .011, and .001, respectively). The percentage change in hsCRP levels after treatment was inversely correlated with baseline hsCRP levels (r = -0.497, P < .001) and directly correlated with the change in postprandial glucose (r = 0.251, P = .021), VFT (r = 0.246, P = .030), and VFT/SFT ratio (r = 0.276, P = .015). Logistic regression analysis revealed that the hsCRP-lowering effect of pioglitazone was affected by baseline hsCRP levels (odds ratio [OR] = 7.929, P = .007) as well as changes in postprandial 2-hour glucose (OR = 0.716, P = .025) and VFT/SFT ratio (OR = 0.055, P = .009). In conclusion, treatment with pioglitazone produced an anti-inflammatory effect, decreasing serum hsCRP levels; and a decrease in the VFT/SFT ratio was independently and most strongly associated with the hsCRP-decreasing effect. These results suggest that abdominal fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment.
    Metabolism: clinical and experimental 02/2011; 60(2):165-72. DOI:10.1016/j.metabol.2009.12.007 · 3.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A preliminary evaluation of the radio transmission performance of an aeronautical digital telephone system with possible application to the terrestrial flight telephone system (TFTS), is presented. Transmission and signaling will be digital within the 1.6 GHz band, using time-division multiple access (TDMA) and time-division multiplexing (TDM) in the air-to-ground and in ground-to-air links, respectively. Many topics must be studied in order to design a spectrum-efficient and toll-quality system. Some of these are addressed, such as propagation and modulation. In particular, first results are provided on the application of the GMSK (Gaussian minimum-shift keying) modulation with coherent demodulation to the aeronautical telephone system, considering the main propagation impairments and the burst-like transmission due to TDMA. As a preliminary result, GMSK turns out to be feasible solution
    Vehicular Technology Conference, 1990 IEEE 40th; 06/1990
Show more